The results of a collaborative study conducted by Cancer Genetics, Inc. and the Cleveland Clinic to validate CGIs kidney cancer microarray test were presented by Cristina Magi-Galluzzi, MD, PhD, of the Cleveland Clinic at the 2014 United States & Canadian Academy of Pathology annual meeting in San Diego in March, according to a news release. The GCI test facilitates the diagnosis, sub-typing and outcome prediction of kidney cancer patients.
The study, Evaluation of a decision tree in the diagnosis of renal neoplasms based on genomic aberrations detected by array-CGH, was completed in conjunction with a team at the Cleveland Clinic that included both the Pathology and Laboratory Medicine and Urological Institutes, according to the release. The study reviewed 15 targeted genomic regions for copy number data across 188 samples of kidney cancer patients treated at the Cleveland Clinic. The study included samples from all major subtypes of renal cancer.
The results support implementation of CGIs kidney cancer microarray test in a clinical setting to provide highly accurate subtyping and outcome prediction for renal cancers. The panel also is being transferred to a next-generation sequencing platform for additional assessment of
Our test has the ability to both subtype and help predict outcome from a small amount of DNA taken from either paraffin-embedded or fine needle aspirate, Panna Sharma, CEO of Cancer Genetics, said in the release. This is very unique and will be a tremendous aid for both pathologists and oncologists helping patients in the battle against kidney cancer.
This study demonstrated the diagnostic sensitivity of the test is 93%, with 99% specificity, according to the release. Accurately diagnosing kidney cancer using pathology alone is challenging and can delay time to first treatment if surgical resections are required, according to the release.
Cancer Genetics is commercializing the test nationally by making it available as a laboratory
For further information
For further information, see CancerGenetics.com.